Toxicity and clinical tolerance of lonidamine
Webtory signs of toxicity were not observed in dogs receiving oral LND. Therefore, this dose and route ap-pear to be viable for in vivo studies. 10,11 Clinical Studies With LND The pharmacokinetics ... WebAbstract BACKGROUND Lonidamine (LND) is an indazol-carboxylic acid derivative that selectively inhibits the energy metabolism of neoplastic cells, and increases the …
Toxicity and clinical tolerance of lonidamine
Did you know?
WebApr 1, 1991 · Toxicity and clinical tolerance of lonidamine. G Robustelli della Cuna Division of Oncology, Istituto di Ricovero e Cura a Carattere Scientifico, Fondazione Clinica del … WebEurope PMC is an archive of life sciences journal literature. Phase I and clinical pharmacologic evaluation of Lonidamine in patients with advanced cancer.
WebJan 1, 2005 · Europe PMC is an archive of life sciences journal literature. Search life-sciences literature (41,607,507 articles, preprints and more) WebNov 11, 2024 · In summary, it should be noted that multiple biological effects, tumor selectivity, and low toxicity to normal tissues are the critical characteristics that make …
WebLonidamine is a derivative of indazole-3-carboxylic acid, which for a long time, has been known to inhibit aerobic glycolysis in cancer cells. It seems to enhance aerobic glycolysis in normal cells, but suppress glycolysis in cancer cells. This is most likely through the inhibition of the mitochondrially bound hexokinase.
WebPlasma lonidamine concentration and toxicity were investigated in dogs receiving 100, 200, 400, 800, 1200 mg/m2 orally twice daily for 30 days and in dogs receiving single intravenous doses of 200, 400, 800, 1200 mg/m2. Physical or laboratory signs of toxicity were not observed in dogs receiving oral lonidamine, but severe vomiting and signs of acute …
WebToxicity was assessed by tracking changes in animal body weight from day 0 through 28 days post-treatment, by measuring plasma levels of the liver enzymes ALT (Alanine Aminotransferase) and LDH (lactate dehydrogenase), and … coral reef pictures freeWebLonidamine was detected in the plasma of all patients, but there was no clear relationship between Lonidamine levels and clinical response or toxicity. Lonidamine appears to be … coral reef population graphWebIn Phase I and II clinical trials LND was shown to be devoid of the characteristic toxic effects of chemotherapeutic agents, such as hematological toxicity. Its main side effects are myalgia, testicular pain and gastric discomfort [11-14]. It does not in- terfere with neurological findings, such as focal defi- famous speech pdfWebSep 1, 1991 · Lonidamine is a substituted indazole carboxylic acid with a unique mechanism of action and early clinical studies have reported anti-tumour activity. famous speech openingsWebLonidamine is a derivative of indazole-3-carboxilic acid and is known for its ability to inhibit aerobic glycolysis in cancer cells [92]. Under hypoxic conditions, as is common with … coral reef protectionWebApr 1, 2002 · Lonidamine (LND) or 1-(2,4-dichlorobenzyl)-1H-indazole-3-carboxylic acid, is an anticancer and an antispermatogenic drug whose mechanism of action is still not completely understood.. Alone or in combination with other therapies, LND is currently used to treat a number of tumors, including head, neck , and breast cancers, causing only minor … coral reef relaxation musicWeb14 hours ago · Study design. NANO-GBM trial is a multicenter, phase I/II, randomized, open-label, non-comparative, therapeutic study. The phase I part consists of a dose escalation with 3 dose levels of AGuIX: 50, 75 and 100 mg/kg, driven by a Time-to-event Continuous Reassessment Method (TITE-CRM) [] with a dose-toxicity relationship given by a one … coral reef protein skimmer